image
Healthcare - Drug Manufacturers - General - NYSE - CH
$ 111.3
-0.289 %
$ 221 B
Market Cap
18.83
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVS stock under the worst case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVS stock under the base case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVS stock under the best case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVS

image
$114.0$114.0$112.0$112.0$110.0$110.0$108.0$108.0$106.0$106.0$104.0$104.0$102.0$102.0$100.0$100.0$98.0$98.0$96.0$96.0$94.0$94.0$92.0$92.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
51.7 B REVENUE
10.85%
14.5 B OPERATING INCOME
48.88%
11.9 B NET INCOME
39.28%
17.6 B OPERATING CASH FLOW
21.86%
-7.51 B INVESTING CASH FLOW
-134.26%
-11.7 B FINANCING CASH FLOW
17.76%
13.6 B REVENUE
2.93%
3.53 B OPERATING INCOME
-2.67%
2.82 B NET INCOME
-11.57%
4.19 B OPERATING CASH FLOW
-33.30%
-3.03 B INVESTING CASH FLOW
-710.96%
-3 B FINANCING CASH FLOW
-684.29%
Balance Sheet Novartis AG
image
Current Assets 29.7 B
Cash & Short-Term Investments 13.4 B
Receivables 9.54 B
Other Current Assets 6.81 B
Non-Current Assets 72.5 B
Long-Term Investments 1.13 B
PP&E 10.9 B
Other Non-Current Assets 60.5 B
13.06 %9.33 %6.66 %10.63 %59.21 %Total Assets$102.2b
Current Liabilities 28.7 B
Accounts Payable 4.57 B
Short-Term Debt 8.32 B
Other Current Liabilities 15.8 B
Non-Current Liabilities 29.4 B
Long-Term Debt 22.9 B
Other Non-Current Liabilities 6.49 B
7.87 %14.32 %27.18 %39.46 %11.17 %Total Liabilities$58.1b
EFFICIENCY
Earnings Waterfall Novartis AG
image
Revenue 51.7 B
Cost Of Revenue 12.8 B
Gross Profit 38.9 B
Operating Expenses 24.4 B
Operating Income 14.5 B
Other Expenses 2.6 B
Net Income 11.9 B
60b60b50b50b40b40b30b30b20b20b10b10b0052b(13b)39b(24b)15b(3b)12bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.20% GROSS MARGIN
75.20%
28.12% OPERATING MARGIN
28.12%
23.09% NET MARGIN
23.09%
27.11% ROE
27.11%
11.68% ROA
11.68%
15.55% ROIC
15.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novartis AG
image
14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 11.9 B
Depreciation & Amortization 6.07 B
Capital Expenditures -3.81 B
Stock-Based Compensation 1.04 B
Change in Working Capital -706 M
Others -1.87 B
Free Cash Flow 13.8 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novartis AG
image
Wall Street analysts predict an average 1-year price target for NVS of $120 , with forecasts ranging from a low of $118 to a high of $121 .
NVS Lowest Price Target Wall Street Target
118 USD 6.02%
NVS Average Price Target Wall Street Target
120 USD 7.52%
NVS Highest Price Target Wall Street Target
121 USD 8.72%
Price
Max Price Target
Min Price Target
Average Price Target
12512512012011511511011010510510010095959090Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
3.28 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
4.000004.000003.500003.500003.000003.000002.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000002.524192.522.474912.472.460572.462.667562.672.56722.573.0423.043.37843.383.3573.363.469363.473.77723.783.277113.282015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Novartis AG
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta. zacks.com - 1 week ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts. fxempire.com - 1 week ago
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? zacks.com - 2 weeks ago
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans. fool.com - 2 weeks ago
Trump Says Pharmaceutical Tariffs Coming in Near Future President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office. youtube.com - 2 weeks ago
Trump says US pharma tariffs coming in not-too-distant future U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future. reuters.com - 2 weeks ago
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog. zacks.com - 2 weeks ago
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports. zacks.com - 3 weeks ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine. cnbc.com - 3 weeks ago
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working. The Company spend billions to produce 100% of its key medicines for Americans in the U.S. barrons.com - 3 weeks ago
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs Swiss pharmaceutical giant Novartis (NVS) said it plans to invest $23 billion in the construction and expansion of 10 U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration. investopedia.com - 3 weeks ago
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration. reuters.com - 3 weeks ago
8. Profile Summary

Novartis AG NVS

image
COUNTRY CH
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 221 B
Dividend Yield 0.00%
Description Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Contact Lichtstrasse 35, Basel, 4056 https://www.novartis.com
IPO Date Nov. 7, 1996
Employees 75883
Officers Dr. Patrick Horber M.D. President of International Mr. Victor Bulto President of US Mr. Harry Kirsch Chief Financial Officer Dr. Vasant Narasimhan M.D. Chief Executive Officer Dr. Linda W. Armstrong M.D. Global Head of Respiratory Development Ms. Karen L. Hale Chief Legal & Compliance Officer Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer Paul Penepent Head of Group Financial Reporting and Accounting Ms. Sloan Simpson Global Head of Investor Relations Dr. Steffen Lang Ph.D. President of Operations